Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Mankind Pharma
MANKIND
Mankind Pharma
Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹2,150.00
16.6% overvalued
intrinsic discount
16 Aug
₹2,506.60
Loading
1Y
9.9%
7D
1.6%
Author's Valuation
₹2.2k
16.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹2.2k
16.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
186b
2019
2021
2023
2025
2027
2028
Revenue ₹186.0b
Earnings ₹31.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.93%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹31.06b
Earnings '28
x
44.72x
PE Ratio '28
=
₹1.39t
Market Cap '28
₹1.39t
Market Cap '28
/
451.15m
No. shares '28
=
₹3.08k
Share Price '28
₹3.08k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹2.15k
Fair Value '25